CD4+ cell count and outcomes among HIV-infected compared with uninfected medical ICU survivors in a national cohort

Background: People with HIV (PWH) with access to antiretroviral therapy (ART) experience excess morbidity and mortality compared with uninfected patients, particularly those with persistent viremia and without CD4(+) cell recovery. We compared outcomes for medical intensive care unit (MICU) survivors with unsuppressed (>500 copies/ml) and suppressed (<= 500 copies/ml) HIV-1 RNA and HIV-uninfected survivors, adjusting for CD4(+) cell count. Setting: We studied 4537 PWH [unsuppressed = 38%; suppressed = 62%; 72% Veterans Affairs-based (VA) and 10 531 (64% VA) uninfected Veterans who survived MICU admission after entering the Veterans Aging Cohort Study (VACS) between fiscal years 2001 and 2015. Methods: Primary outcomes were all-cause 30-day and 6-month readmission and mortality, adjusted for demographics, CD4(+) cell category (>= 350 (reference); 200-349; 50-199; <50), comorbidity and prior healthcare utilization using proportional hazards models. We also adjusted for severity of illness using discharge VACS Index (VI) 2.0 among VA-based survivors. Results: In adjusted models, CD4(+) categories <350 cells/mu l were associated with increased risk for both outcomes up to 6 months, and risk increased with lower CD4(+) categories (e.g. 6-month mortality CD4(+) 200-349 hazard ratio [HR] = 1.35 [1.12-1.63]; CD4(+) <50 HR = 2.14 [1.72-2.66]); unsuppressed status was not associated with outcomes. After adjusting for VI in models stratified by HIV, VI quintiles were strongly associated with both outcomes at both time points. Conclusion: PWH who survive MICU admissions are at increased risk for worse outcomes compared with uninfected, especially those without CD4(+) cell recovery. Severity of illness at discharge is the strongest predictor for outcomes regardless of HIV status. Strategies including intensive case management for HIV-specific and general organ dysfunction may improve outcomes for MICU survivors.